{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:18:23Z","timestamp":1790936303226,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00347-018-0700-6","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T08:44:47Z","timestamp":1523609087000},"page":"464-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Langzeiteffekte der Anti-VEGF-Therapie bei Fr\u00fchgeborenenretinopathie","Long-term effects of anti-VEGF therapy for retinopathy of prematurity"],"prefix":"10.1007","volume":"115","author":[{"given":"T. U.","family":"Krohne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC et\u00a0al (2017) Systematic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina 37:1847\u20131858. https:\/\/doi.org\/10.1097\/IAE.0000000000001493","journal-title":"Retina"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"S-N Chen","year":"2015","unstructured":"Chen S\u2011N, Lian I, Hwang Y\u2011C et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 35:667\u2013674. https:\/\/doi.org\/10.1097\/IAE.0000000000000380","journal-title":"Retina"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaapos.2014.03.011","volume":"18","author":"W Chen","year":"2014","unstructured":"Chen W, Binenbaum G, Karp K et\u00a0al (2014) Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser. J\u00a0Aapos 18:402\u2013404. https:\/\/doi.org\/10.1016\/j.jaapos.2014.03.011","journal-title":"J Aapos"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jaapos.2004.12.018","volume":"9","author":"E Garcia-Valenzuela","year":"2005","unstructured":"Garcia-Valenzuela E, Kaufman LM (2005) High myopia associated with retinopathy of prematurity is primarily lenticular. J\u00a0Aapos 9:121\u2013128. https:\/\/doi.org\/10.1016\/j.jaapos.2004.12.018","journal-title":"J Aapos"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et\u00a0al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a\u00a0randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.2772","journal-title":"JAMA Ophthalmol."},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5935\/0004-2749.20150079","volume":"78","author":"M Gunay","year":"2015","unstructured":"Gunay M, Celik G, Gunay BO et al (2015) Evaluation of 2\u2011year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 78:300\u2013304. https:\/\/doi.org\/10.5935\/0004-2749.20150079","journal-title":"Arq Bras Oftalmol"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S et\u00a0al (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155:1119\u20131124.e1. https:\/\/doi.org\/10.1016\/j.ajo.2013.01.014","journal-title":"Am J Ophthalmol"},{"key":"700_CR8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ et\u00a0al (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006","journal-title":"Arch Ophthalmol"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5\u2011year retrospective analysis. Ophthalmology 122:1008\u20131015. https:\/\/doi.org\/10.1016\/j.ophtha.2014.12.017","journal-title":"Ophthalmology"},{"key":"700_CR10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00347-008-1841-9","volume":"105","author":"C Jandeck","year":"2008","unstructured":"Jandeck C, Kellner U, Lorenz B, Seiberth V (2008) Guidelines for ophthalmologic screening of premature infants. Ophthalmologe 105:955\u2013963","journal-title":"Ophthalmologe"},{"key":"700_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00347-012-2618-8","volume":"109","author":"TU Krohne","year":"2012","unstructured":"Krohne TU, Aisenbrey S, Holz FG (2012) Current therapeutic options in retinopathy of prematurity. Ophthalmologe 109:1189\u20131197. https:\/\/doi.org\/10.1007\/s00347-012-2618-8","journal-title":"Ophthalmologe"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00347-013-2932-9","volume":"111","author":"TU Krohne","year":"2014","unstructured":"Krohne TU, Holz FG, Meyer CH (2014) Pharmacokinetics of intravitreally administered VEGF inhibitors. Ophthalmologe 111:113\u2013120. https:\/\/doi.org\/10.1007\/s00347-013-2932-9","journal-title":"Ophthalmologe"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu M\u2011H, Hsu K\u2011H et al (2016) Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11:e148019. https:\/\/doi.org\/10.1371\/journal.pone.0148019","journal-title":"PLoS ONE"},{"key":"700_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/EB.S99306","volume":"8","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM (2016) Review of effects of anti-VEGF treatment on refractive error. Eye Brain 8:135\u2013140. https:\/\/doi.org\/10.2147\/EB.S99306","journal-title":"Eye Brain"},{"key":"700_CR15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N\u00a0Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-Hittner","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845\u20131855. https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"},{"key":"700_CR17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et\u00a0al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"},{"key":"700_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0161-6420(00)00527-3","volume":"108","author":"GE Quinn","year":"2001","unstructured":"Quinn GE, Dobson V, Siatkowski R et\u00a0al (2001) Does cryotherapy affect refractive error? Results from treated versus control eyes in the cryotherapy for retinopathy of prematurity trial. Ophthalmology 108:343\u2013347","journal-title":"Ophthalmology"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jaapos.2012.10.025","volume":"17","author":"GE Quinn","year":"2013","unstructured":"Quinn GE, Dobson V, Davitt BV et\u00a0al (2013) Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings at 4 to 6 years of age. J\u00a0Aapos 17:124\u2013128. https:\/\/doi.org\/10.1016\/j.jaapos.2012.10.025","journal-title":"J Aapos"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00347-011-2519-2","volume":"109","author":"Retinologischen Gesellschaft","year":"2011","unstructured":"Retinologischen Gesellschaft, Deutsche Ophthalmologische Gesellschaft, Berufsverband der Augen\u00e4rzte Deutschland (2011) Stellungnahme der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbands der Augen\u00e4rzte Deutschlands zum Einsatz von Bevacizumab in der Therapie der Fr\u00fchgeborenenretinopathie, Stand: 20.12.2011. Ophthalmologe 109:197\u2013204. https:\/\/doi.org\/10.1007\/s00347-011-2519-2","journal-title":"Ophthalmologe"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"W-C Wu","year":"2015","unstructured":"Wu W\u2011C, Lien R, Liao P\u2011J et al (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. Jama Ophthalmol 133:391\u2013397. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5373","journal-title":"Jama Ophthalmol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0700-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0700-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0700-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:36:48Z","timestamp":1536539808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0700-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0700-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}